Monte Rosa Therapeutics, Inc. GLUE Accrued Liabilities & Other
Accrued Liabilities & Other at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s accrued liabilities & other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s accrued liabilities & other?
- Monte Rosa Therapeutics, Inc. (GLUE) reported accrued liabilities & other of $25.59M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s accrued liabilities & other changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s accrued liabilities & other increased by 57.1% year-over-year, from $16.29M to $25.59M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s accrued liabilities & other?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s accrued liabilities & other has grown at a 60.2% compound annual growth rate (CAGR), from $2.53M to $26.69M.
- What does accrued liabilities & other mean?
- Combined accrued expenses and miscellaneous current liabilities not classified in specific categories.